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Abstract
We conducted a systematic review (SR) of the peer reviewed scientific literature on ultraweak photon emissions (UPE) from
humans. The question was: Can ultraweak photon emissions from humans be used as a non-invasive health assessment? A
systematic search was conducted across eight relevant databases: PubMed/MEDLINE, BIOSIS, CINAHL, PSYCHINFO, All of
Cochrane EBM databases, GIDEON, DoD Biomedical Research, and clinicaltrials.gov from database inception to October
2011. Of the 1315 studies captured by the search strategy, 56 met the inclusion criteria, out of which 1 was a RCT, 27 were
CCT, and 28 were observational and descriptive studies. There were no systematic reviews/meta-analyses that fit the
inclusion criteria. In this report, the authors provide an assessment of the quality of the RCT included; describe the
characteristics of all the included studies, the outcomes assessed, and the effectiveness of photon emission as a potential
health assessment tool. This report demonstrates that the peer reviewed literature on UPE and human UPE measurement in
particular is surprisingly large. Most of the human UPE literature is of good to high quality based on our systematic
evaluation. However, an evaluation tool for systematically evaluating this type of ‘‘bio-evaluation’’ methodology is not
currently available and would be worth developing. Publications in the peer reviewed literature over the last 50 years
demonstrate that the use of ‘‘off-the-shelf’’ technologies and well described methodologies for the detection of human
photon emissions are being used on a regular basis in medical and research settings. The overall quality of this literature is
good and the use of this approach for determining inflammatory and oxidative states of patients indicate the growing use
and value of this approach as both a medical and research tool.
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Introduction
Bioluminescence is the process of production and emission of
light by a living organism via chemiluminescence-based processes.
Many examples are known in biology such as fireflies, Antarctic
krill, fungi (for instance Panellus stipticus), various squid species, etc.
In fact, all cells produce some form of light emission, but most of
this light is not visible to the unaided human eye. This photonic
emission has characteristic wavelengths, duration, timing and
patterns of flashes. These are features often associated with
information and, while not proof in and of itself, it is reasonable to
assume that these light emissions contain and carry information
about the biological systems that produced it.
Ultraweak photon emission by living systems, sometimes called
low level chemiluminescence, is the result of normal biochemical
reactions in which electrons transition in and out of electronically
excited states. Detection and identification of these excited states is
easily achieved in well-defined chemical systems. However, the
task becomes more problematic in complex biological systems,
e.g., in studies of isolated cells, organs, or intact organisms.
The advent of new photon counting technologies in the early
1960’s provided the tools to demonstrate the existence of a
ubiquitous low level luminescence in organisms. This provided
convincing evidence that light from living organisms was not
restricted to life forms having special organs containing enzyme
systems such as luciferase/luciferin. This early work was primarily
done in the USSR [1,2] with a few exceptions [3]. Russian
research was sometimes translated into English [4]. By that time it
had been established in inorganic chemical systems that chemi-
luminescence could occur in oxidative reactions as a consequence
of the recombination of oxygen-containing radicals [5,6] and thus
provided information about radical reactions and oxidation
mechanisms. Outside the USSR, the existence of this radiation
was neglected or considered a phenomenon that could be caused
by external interferences of an unknown nature [7]. In the 1970’s,
the existence of this photonic emission from living organisms was
confirmed by research teams from Australia [8], Poland [9], Japan
[10] and the USA [11]. Emissions are in the order of 10-
104 photons/s.cm2, and have been demonstrated in bacteria,
yeast, whole animals and plants as well as cells and homogenates
from organisms.
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For yeasts (Saccharomyces cerivisiae and Schizosaccharomyces
pombe) it was established that ultraweak photon emission was
dependent on oxygenation and that spectral composition differed
between the exponential growth and the stationary phase of the
culture [8,12,13,14]. Similar studies were later performed on the
bacterium Escherischia coli [15,16]. In mammalian systems UPE
was studied at the organ, cellular and subcellular level. Ultraweak
photon emission of rat liver was oxygen dependent, and increased
by infusion of hydroperoxides. Spectral analysis indicated a
predominance of red light-emitting species arising from the singlet
oxygen dimole-emission peaks [11,17]. Similar spectral data as
well as oxygen dependency were obtained with isolated hepato-
cytes. Estimations of biochemical markers of lipid peroxidation
combined with counts of photon emission led to the conclusion
that UPE monitors the steady state concentration of singlet
molecular oxygen [10,11,17,18,19]. Therefore, ultraweak photon
emission can provide a useful tool to examine oxygen-dependent
radical damage which affords an advantage over parameters (such
as malondialdehyde levels) measuring accumulative effects.
Since the early 1980’s, it has been known that peroxidal lipid
reactions are important components in the etiology of diabetes,
liver and lung diseases, arteriosclerosis, ageing and cancer
[20,21,22,23,24]. The production of oxygen radicals during the
respiratory burst of phagocytic cell activity plays an essential role
in bacterial killing and in regulating the processes of acute
inflammation [25,26]. In view of the damaging effects of oxygen
radicals on tissues, it follows that anything causing abnormal
activation of phagocytes has the potential to provoke a self-
destructive response, most strikingly seen in autoimmune diseases
[27]. This realization led to the idea that ultraweak photon
emission determined in blood might be a general marker for
health and could be used for diagnostic and clinical purposes
[28,29]. Early studies established the interdependence between
various diseases and UPE intensity by measuring the differences
between the luminescence of the blood of healthy and diseased
human subjects. UPE of blood from patients with diabetes
mellitus, carcinomas and hyperlipidemia showed higher emission
levels than those of the samples from healthy people [28].
The development of a diagnostic assay based on ultraweak
photon emission remained limited due to difficulties and
requirements of ultra-high sensitive photon counting systems in
the application to biomedical measurements [10,28]. The use of
chemiluminigenic probes - substances whose oxidation gives a
high yield of electronically excited products – solved many of these
issues by increasing the photon output by several orders of
magnitude. For this purpose luminol at concentration 0.1–10 mM
has been employed, for instance in assays of phagocytosis
[25,30,31,32]. Lucigenin has also been sporadically used as a
chemiluminigenic enhancer [26].
The next great challenge for the field of ultraweak photon
emission detection (in relation to oxidative processes) was to
provide images of these low signals in addition to physiological
information. A two-dimensional photon counting imaging of a
rat’s brain was technically achieved in 1999 [33,34]. The
equipment used in this first experiment consisted of a two-
dimensional photon counting tube, a highly efficient lens system,
and an electronic device to record time series of a photoelectron
train with spatial information. Another application of two-
dimensional imaging of these photon emissions has been in the
field of cancer. In bladder cancer, transplanted into the feet of
nude mice, the increase in photon emission in early developing
cancer indicates the actively proliferating cancer before any
detection of necrosis, haemorrhage, leukocyte infiltration or crusta
formation [35]. Cancer imaging in mice transplanted with ovarian
cancer cells utilizing a highly sensitive charge-coupled device
(CCD) camera system has confirmed the increased UPE of
tumours [36].
The major trends over the last 50 years are schematically shown
in Figure 1. Since the original observation of the effect, UPE
detection methodology has matured to be uniquely positioned for
not only providing insight into detailed biochemical processes but
also provide a non-invasive tool for observing and even
understanding system organisation.
Knowledge of the excitation state of biochemical reactions in
organisms and isolated biological systems is of significant value for
assessing basic biological function. In the case of whole organisms,
a general and often specific assessment of health and wellness is
possible with knowledge of the ‘‘reactive’’ or relative excitation
state of intrinsic biochemical reactions. Therefore, it is possible,
using detection and quantification of ultraweak photon emission,
to non-invasively assess a person’s health, specifically the level of
stress on biochemical and metabolic systems from the production
of reactive oxygen species (ROS) as ROS are the principle source
of these photons [5,6,22]. The 50 years of progress in this field has,
thanks to advances in technologies for measuring ultraweak
photon emissions, led to the emerging discipline of ‘human photon
emission’.
To date, there have been no reviews of the literature to ascertain
if ultraweak photon emission can be effectively used as a non-
invasive health assessment tool. The purpose of this systematic
review was to: 1) survey the literature on ultraweak photon
emissions as they relate to human studies; 2) assess the quantity
and quality of the research found; and 3) characterize the results
by whether the study had an intervention or not, 4) what research
model was studied, and 5) the potential value of using photons as a
health assessment tool.
Materials and Methods
Search strategy
A systematic search was conducted across eight relevant
databases: PubMed/MEDLINE, BIOSIS, CINAHL, PSY-
CHINFO, All of Cochrane EBM databases, GIDEON, DoD
Biomedical Research, and clinicaltrials.gov from database incep-
tion to October 2011. The keywords related to photon were pre-
identified by the team with guidance from subject matter experts.
The final search terms decided upon and searched across
databases were: photon, external bioenergy, spontaneous photon
emission, ultraweak photon emission, ultraweak chemilumines-
cence, low level light emission, spontaneous chemiluminescence,
ultraweak photons, ultra-weak photon emission, ultra-weak
photons, ultra-weak chemiluminescence. See Appendix S1 for a
full detail of the search in PubMed. Variations of this strategy were
adapted for each unique database and are available upon request.
The search was limited to English language and human
population only where databases allowed for these limitations.
There was no limitation to study design in the initial search. Grey
literature was searched by accessing and communicating with
subject matter experts in the field and sharing their database
collections as a cross reference to what the original search strategy
retrieved as well as conducting basic internet searching across the
keyword scheme. The reviewers also hand-searched bibliographies
of all included studies to ensure that a comprehensive search
strategy was used.
Selection criteria
All study designs were included, however, for the purpose of the
analysis, only the controlled clinical trial (CCT) and randomized
Biophoton Systematic Review
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control trial (RCT) study designs were considered. Studies were
included in the analysis if they were: 1) in human populations, 2)
describing the use of photons as a health assessment tool, 3) used in
comparison with a placebo control or untreated control for the
systematic review assessment, and 4) measuring ultraweak photon
emission. Studies were excluded if they were categorized as:
thought pieces, descriptive reviews, editorials, and all studies
relating primarily to the physics of photons.
Study selection
Three reviewers independently screened the titles and abstracts
of all retrieved references according to the inclusion criteria
presented above. All studies had to have some discussion
concerning intrinsic light from live subjects in order to be
considered for inclusion. Full text articles were pulled for all
publications where a reviewer felt there was a potential for meeting
inclusion criteria. At this point all study designs were included.
Quality assessment and data extraction
The retrieved full-text articles were put into buckets of study
designs by RCT, CCT, observational, descriptive, and mixed
methods in order to assess the quantity and quality, and describe
the characteristics of the individual included studies.
The RCT study design was assessed for quality according to the
Scottish Intercollegiate Guidelines Network (SIGN 50) [37], a
well-accepted and validated tool for assessing quality used widely
in both complementary and alternative medicine (CAM) and
conventional literature (see Table 1 for a full description of the
SIGN 50 criteria). Because all of the rest of the studies reported
here involved photons as an adjunctive assessment of the
inflammatory state and not as the primary diagnostic assessment
or necessarily including an intervention per se, the authors felt that
the full SIGN criteria was not a good fit for evaluating the quality
of the photonic portion of these studies. After examining the other
quality assessment tools, the authors decided that none fit the
photonic literature examined here. Because of this, the CCT study
designs were only assessed across one of the criteria addressed in
SIGN that fit. The other study designs (observational, descriptive
and mixed methods) were only tallied as to how many fit the
inclusion criteria laid out above.
A data extraction form was created during the protocol
development stage and tested by the team before use. This form
captured details on the system of research, the objective of the
study, the conditions and descriptions of the study population, the
type of control, the specific outcomes and results related to photon
emission and the authors’ main conclusions in order to provide a
descriptive detail of the characteristics of the included studies.
All five reviewers were trained in the methodology for quality
assessment and data extraction by the review manager (C.C.) and
a rule book was created to assist in answering the questions
objectively and consistently, which ensured reproducibility in the
end, which was pilot tested among the team members. Forms were
created in an online system offered through the Samueli Institute’s
Figure 1. Major trends in UPE developments in the last 50 years. The historical development of this field can be subdivided in five main
areas: (1) the initiation of research of UPE with photomultiplier tubes in USSR and its connection to radical oxygen species (ROS) and lipid
peroxidation, (2) the recognition of UPE world wide and globalization of this research, (3) the use of UPE as a non-invasive diagnostic marker, (4) the
extension of time measurement into spatial patterns, and (5) the use of photon count distributions (PCD) and statistics (PCS) (based on fluctuations in
the number of photons in successive counting in contiguous measurement times) for detecting a ‘light language’ that is connected with the system’s
organization of the living biological state.
doi:10.1371/journal.pone.0087401.g001
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SharePoint cite to allow the reviewers to complete the data
extraction. The 5 trained reviewers simultaneously extracted the
data independently of each other (two reviewers assigned to each
individual article) and all answers were tracked through this
system. Any and all conflicts were resolved through discussions in
team meetings. Once collected, all data was downloaded into an
Excel table for each study and formatted in preparation for
inclusion in Tables 2–4.
All included studies were then characterized as to whether there
was an intervention and what system of research they fell into
(whole body, cells [blood cells, other cells], fluids [blood plasma,
urine, cerebral fluid, saliva], and other [tissue]). These categories
were chosen not only because the articles naturally broke into
these categories but also they make intrinsic bio-medical sense.
The effect size was not calculated due to the heterogeneity of the
trials identified during the review phase. All assessments were
Table 1. SIGN 50 Checklist for RCT Study Design.
Section 1: Internal validity
Each item in Section 1 is to be evaluated using these criteria: 1) Well Covered, 2) Adequately Addressed, 3) Poorly Addressed, and 4) Not Applicable
(NA) only for question 1.10.
ITEM DESCRIPTION
1.1 The study addresses appropriate and clearly focused question.
1.2 The assignment of subjects to treatment groups is randomized.
1.3 An adequate concealment method is used.
1.4 Subjects and investigators are kept blind about allocation.
1.5 The treatment and control groups are similar at the start of the trial.
1.6 The only difference between groups is the treatment under investigation.
1.7 All relevant outcomes are measured in a standard, valid and reliable way.
1.8 What percentage of subjects in each treatment arm dropped out before the study was completed?
1.9 All subjects are analyzed in the groups to which they were randomly allocated (intention to treat analysis).
1.10 Where the study is carried out at more than one site, results are comparable for all sites.
Section 2: Overall Assessment
How well was the study done to minimize bias? How valid is the study? Score options: ++, +, – based on following (modifications to SIGN criteria in
italics):
++ All or most of the criteria have been fulfilled. Where they have not been fulfilled the conclusions of the study are thought very unlikely to alter. An article
receives this score if there are 0 criteria scored as poorly addressed.
+ Some of the criteria have been fulfilled. Those criteria that have not been fulfilled or not adequately described are thought unlikely to alter the conclusions.
An article receives this score if 1-2 criteria are scored poorly addressed.
- Some of the criteria have been fulfilled. Those criteria that have not been fulfilled or not adequately described are thought unlikely to alter the conclusions.
An article receives this score if 1-2 criteria are scored poorly addressed.
Note that only the RCT in Table 2 was assessed across all quality criteria in SIGN 50. For all CCT study designs in Tables 3 and 4, only criteria 1.1 appeared relevant to the
focus of the study and therefore only scored for that criterion. See limitations section of the manuscript for a description of this challenge.
SIGN 50 Network: A Guideline Developer’s Handbook http://www.sign.ac.uk/guidelines/fulltext/50/checklist2.html
doi:10.1371/journal.pone.0087401.t001
Table 2. Descriptive data for randomized controlled trials that have an intervention.
Citation Objective of Study Condition Group Control
Results for outcome
related to UPE
Author’s Main Conclusion for
Outcome of Interest
SIGN50
Score
Schutgens
et al. 2009
To study the effect of
plant adaptogens
(Rhodiola rosea and
ADAPT-232) on human
UPE by measuring
dorsal side of left
and right hands.
10 (of 30) subjects with a
mean age of 23.3, BMI of
21.7, and WHI of 0.87.
5 females and 5 males.
P The Rhodiola group showed
a statistically significant
decrease in UPE (p = 0.027;
pre = 2.94 and post = 1.72)
in comparison with the
placebo group (pre = 2.30 and
post = 2.81). The ADAPT-232
and placebo groups had no
significant changes (p = 0.199),
although there was slight
decrease in UPE in ADAPT-
232 (pre = 2.39 and post = 1.82). *
Rhodiola rosea (SHR-5) reduced the
experienced level of fatigue in
comparison to the placebo group
(p = 0.049). Both adaptogens
(ADAPT-232 as well as Rhodiola
rosea were able to reduce UPE
from the dorsal side of both hands.
Only Rhodiola rosea reduced UPE
significantly compared to placebo
(p = 0.027).
+
P = Placebo
doi:10.1371/journal.pone.0087401.t002
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based on information provided in the published manuscripts that
met the inclusion criteria.
Results
Of the 1315 studies captured by our search strategy, 56 met the
inclusion criteria, out of which 1 was a RCT, 27 were CCTs, and
28 were observational and descriptive studies. There were no
systematic reviews/meta-analyses that fit our inclusion criteria.
See Figure 2 for a graphical depiction of the study selection and
elimination process throughout the review phases. In this report,
the authors provide an assessment of the quality of the RCT
included; describe the characteristics of all the included studies, the
outcomes assessed, and the effectiveness of photon emission as a
potential health assessment tool. The RCT and CCT study
designs are presented descriptively in Tables 2–4. Other formal
study designs included are narratively summarized below and will
be reported on in more detail in future publications.
Quality assessment of RCT
Of the 56 included studies, only one was categorized as a RCT.
In this study, the effect of plant adaptogens on human ultraweak
photon emission was determined by providing subjects with
supplements of Rhodiola rosea, placebo pills, or ADAPT-32 (mix of
adaptogens) for one week, and measuring the ultraweak photon
emission from the dorsal side of their hands. The results show a
significant decrease in photon emission (p = 0.027), as well as in
reported fatigue levels (p = 0.049) in the Rhodiola group compared
to the placebo group. However, this work would have been better
with the groups approximately matched for age. This RCT
received an overall quality score of (+) according to the SIGN 50
criteria. The authors did not provide a full description of the
randomization process and allocation concealment methodology
in the published report. Although they did not address these
important components, because of the strength in the other
criteria assessed the conclusions of the study are thought unlikely
to be altered by the inclusion of this missing information. We also
believe there is a low level of bias being introduced to this study.
Further studies employing an RCT design are needed to
determine the value of photon emission measurement as a tool
for assessing the impact of supplement use as well as other
interventions meant to improve health. See Table 2 for further
details of the study [38].
Controlled clinical trials
Of the 56 included studies, 27 were characterized as CCT study
design, out of which 17 studies involved no intervention (Table 4)
while the remaining 11 studies had an intervention (Table 3). It is
interesting to note that most interventional studies came up in the
literature post-2003 with the exception of Hans 1997 [39],
whereas all of the research in the last two decades of the 1900’s
(1982–2003) involved no intervention. In the Hans study, the
effect of total intravenous anesthesia on the plasma antioxidant
capacity of neurosurgical patients during a cerebrospinal shunt
was studied. It was a first of its kind to measure ultraweak
chemiluminescence of patients’ plasma before and after an
intervention. All the other research was focused on assessing and
comparing the state of inflammation among different groups for
future diagnosis purposes. These studies were grouped by their
system of research. The most commonly studied system of research
was blood cells (9) [40,41,42,43,44,45,46,47,48] followed by whole
body (8) [49,50,51,52,53,54,55,56], blood plasma (4)
[39,57,58,59], tissues (2) [60,61], urine (2) [62,63], saliva (1)
[64], and other cells (1) [65].
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The inflammatory states studied in the various publications
included respiratory inflammations such as anthrax, chronic
bronchitis, pneumonia, lung injury, and smoking as well as a
number of other conditions such as, ulcerative colitis, multiple
sclerosis, cancer, ankylosing spondylitis, hemodialysis, and varico-
cele. There were three studies [53,54,56] that looked at the
ultraweak photon emission of experienced meditation practitioners
compared to practitioners with no experience. All three studies
found decreased photon emission in the experienced meditation
groups compared to the control groups.
Observational and descriptive studies
Of the 56 included studies, 28 were characterized as observa-
tional and descriptive studies, out of which 20 studies used whole
bod-
y[56,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84],
3 blood cells[85,86,87], 3 saliva[64,88,89], 1 blood plasma[90],
and 1 breath[91] as systems of research. The details of these
studies will be reported on in future publications.
Discussion
Main findings
Publications in the peer reviewed literature over the last 50
years clearly demonstrate that the use of ‘‘off-the-shelf’’ technol-
ogies and well described methodologies for the detection of human
photon emissions are being used on a regular basis in medical and
research settings. Our search turned up only one RCT. While of
good quality (SIGN score of ‘‘+’’), clearly this field needs more
RCTs to truly test the use of UPEs as a diagnostic tool. The overall
quality of this literature is good and the use of this approach in
medical oncology settings for determining inflammatory and
oxidative states of patients indicate the growing use and value of
this approach.
Strength and limitations
Because of this system of research, there is no quality rating tool
available in the literature to accurately assess the quality of UPE
research. This type of research is neither diagnostic as defined in
some of the quality tools for diagnostic studies nor do the studies
Figure 2. Flow chart. There were a total of 1315 records identified through the literature search, out of which 1113 were screened based on
abstracts after removal of duplicates. The first level of screening based on abstracts resulted in exclusion of 1048 records (descriptive reviews,
editorials, theories, books, book sections, non-human studies, and grey literature that didn’t fit our inclusion criteria), and the second level of
screening based on full-text resulted in exclusion of 9 more additional records. Therefore, a total of 56 studies (1 randomized controlled clinical trial,
27 controlled clinical trials, and 28 observational/descriptive studies) were included in this review.
doi:10.1371/journal.pone.0087401.g002
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we found consist of clinical trials with clearly defined intervention
and control. SIGN 50 Diagnostic Tool for assessing quality looks
at whether the results reflect the accuracy of the diagnostic test
being evaluated. This is not what these groups of studies did as
they were looking at photons as an adjunctive assessment of the
inflammatory state and not as the primary diagnostic assessment,
or including an intervention necessarily which made finding a tool
to fit these designs of studies very challenging [37]. Other tools
were explored and they too did not fit within the scope of the
research examined in this review. The limitation of this systematic
review is that we are not able to fully comment on the overall
quality of these studies captured in this review without this tool in
place. Since this research seems promising, it would be worthwhile
to determine how best to assess quality of this system of research
for future reviews. We were however able to document the
quantity of the literature that exists in a rigorous, systematic way in
this area and describe the literature as it exists today which is
beneficial to understanding how it could be used as a health
assessment tool and what has been done to date using this method.
Since this research seems promising, it would be worthwhile to
determine how best to assess quality of this system of research for
future reviews. At this point, provided this limitation, the authors
can only say subjectively that the quality is ‘‘good’’ for the CCT
study designs evaluated.
Implications for research
Technological advances and improved understanding of the
underlying biology have combined to enable the measurement of
human photons in a rapid and reliable manner. The technology
has advanced sufficiently to allow for non-invasive whole body
measurements of these relatively rare photons and there is some
evidence that measuring from the hands is sufficient [92]. This has
the potential to provide both the researcher and the diagnostician
with a powerful tool to look within the body, in real-time, at the
fundamental biochemistry and production of ROS and corre-
spondingly the REDOX state of the metabolism [93]. While the
production of ROS is an unavoidable by-product of metabolism
[94], when it is not properly managed by the body or when it is
excessive as under certain kinds of stress [95,96] it can lead to a
number of pathologies.
As ROS have been shown to be associated with a number of
disease states it is clearly of use to assess their presence and
prevalence. Therefore, assessing ROS levels may be useful for
tracking the impact of various interventions, behaviors or
medications. Doing so in a non-invasive and easy way is of great
import.
Conclusion
Our study demonstrates that the peer reviewed literature
around UPE and human UPE measurement in particular is
surprisingly large. Most of the human UPE literature is of good to
high quality based on our systematic evaluation. However, an
evaluation tool for systematically evaluating this type of ‘‘bio-
evaluation’’ methodology is not currently available and would be
worth developing. The authors applied their experience in
performing systematic reviews to perform this evaluation from
the available tools.
In addition, the field of human photon detection and the
technology for measuring same has matured to the point where
RCTs should be performed. In this way, it will be possible to
determine if this approach can deliver a tool for non-invasively
evaluating the specific inflammatory state of the individual while
simultaneously providing a general measure of overall health.
Finally, detection of human photon emissions has the potential for
broad applicability to human health and disease monitoring at the
whole systems level.
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